Late progression of renal cell carcinoma after 32 years: clinical case

Cover Page

Cite item

Full Text

Abstract

In 2022, renal cell carcinoma was the 10th (3.9 %) most common cancer in the Russian Federation. According to the World Health Organization, in 2020 431,288 new cases of kidney cancer were detected worldwide, and by 2040 the incidence will increase up to 605,726 cases. Local recurrence of the disease develops in 1.8–14.6 % of patients with localized and locally advanced kidney cancer who underwent radical nephrectomy. Surgery, if technically possible, is the gold standard for the treatment of patients with solitary or single (≤2) metastases of any location, and in most cases, it requires aggressive tactics.

Many large randomized trials have investigated adjuvant therapy using targeted drugs for renal cell carcinoma but no statistically significant differences in risk of death and progression irrespective of the drugs used or treatment duration has been shown. Currently, only the KEYNOTE-564 randomized trial has demonstrated an increase in recurrencefree survival in patients with intermediate-high and high risk renal cell carcinoma.

The article presents a clinical case of late progression of renal cell carcinoma in extraperitoneal lymph nodes 32 years after combination treatment (radical nephrectomy + external beam radiotherapy on the bed of the resected kidney).

About the authors

L. O. Petrov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia;
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: leonid_petrov@mail.ru
SPIN-code: 4559-3613

Leonid Olegovich Petrov

10 Marshala Zhukova St., Obninsk 249031;
3 2nd Botkinskiy Proezd, Moscow 125284

 

Russian Federation

A. A. Izmailov

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: albertizmailov96@gmail.com
ORCID iD: 0000-0001-5836-0066
SPIN-code: 5123-3920

3 2nd Botkinskiy Proezd, Moscow 125284

A. V. Ustimenko

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: andrew.ustim@gmail.com
SPIN-code: 9345-8711

10 Marshala Zhukova St., Obninsk 249031

A. S. Kalpinskiy

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: dr.kalpinskiytrial@gmail.com
ORCID iD: 0000-0002-2209-3020
SPIN-code: 7253-9356

3 2nd Botkinskiy Proezd, Moscow 125284

A. A. Izmailov

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-8461-9243

73/1 Oktyabrya Prospekt, Ufa 450054

Russian Federation

B. Ya. Alekseev

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia;
Russian Biotechnological University

Email: byalekseev@mail.ru
ORCID iD: 0000-0002-3398-4128
SPIN-code: 4692-5705

Department of Oncology, Medical Institute of Continuing Education RusBioTech

10 Marshala Zhukova St., Obninsk 249031; 
11 Volokolamskoe Shosse, Moscow 125080

Russian Federation

S. A. Ivanov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: ivanov.obninsk@mail.ru
SPIN-code: 4264-5167

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

References

  1. Malignant tumors in Russia in 2022 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova, I.V. Lisichnikova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023. 275 p. (In Russ.).
  2. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. doi: 10.3322/caac.21660
  3. Bianchi M., Sun M., Jeldres C. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23(4):973–80. doi: 10.1093/annonc/mdr362
  4. Esrig D., Ahlering Т.Е., Lieskovsky G., Skinner D.G. Experience with fossa recurrence of renal cell carcinoma. J Urol 1992;147(6):1491–4. doi: 10.1016/s0022-5347(17)37605-x
  5. Pischon T., Lahmann P.H., Boeing H. et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728–38. doi: 10.1002/ijc.21398
  6. Petejova N., Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160(2):183–94. doi: 10.5507/bp.2015.050
  7. Sasco A.J., Secretan M.B., Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004;45(Suppl 2):S3–9. doi: 10.1016/j.lungcan.2004.07.998
  8. Chittiboina P., Lonser R.R. Von Hippel–Lindau disease. Hand Clin Neurol 2015;132:139–56. doi: 10.1016/B978-0-444-62702-5.00010-X
  9. Клинические рекомендации. Рак паренхимы почки, 2021. Доступно по: https://cr.minzdrav.gov.ru/recomend/10Clinical Guidelines. Kidney parenchyma cancer, 2021. Available at: https://cr.minzdrav.gov.ru/recomend/10 (In Russ.).
  10. Bruckschen F., Gerharz C.D., Sagir A. Renal cell carcinoma with unusual metachronous metastasis up to 22 years after nephrectomy: two case reports. J Med Case Rep 2021;15(1):490. doi: 10.1186/s13256-021-03098-5
  11. Alayyaf N., AlQatari A.A., Altalib A. et al. Management of very late pancreatic metastasis of renal cell carcinoma 8 years after radical nephrectomy: a report of a rare case. Am J Case Rep 2021;22:e927921. doi: 10.12659/AJCR.927921
  12. Cheaib J.G., Patel H.D., Johnson M.H. et al. Stage-specific conditional survival in renal cell carcinoma after nephrectomy. Urol Oncol 2020;38(1):6.e1–7. doi: 10.1016/j.urolonc.2019.08.011
  13. Tanguay S., Pisters L.L., Lawrence D.D., Dinney C.P. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 1996;155(1):26–9.
  14. Haas N.B., Manola J., Uzzo R.G. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial [published correction appears in Lancet 2016;387(10032):1998]. Lancet 2016;387(10032):2008–16. doi: 10.1016/S0140-6736(16)00559-6
  15. Haas N.B., Manola J., Dutcher J.P. et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol 2017;3(9):1249–52. doi: 10.1001/jamaoncol.2017.0076
  16. Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35(35):3916–23. doi: 10.1200/JCO.2017.73.5324
  17. Sun M., Marconi L., Eisen T. et al. Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis. Eur Urol 2018;74(5):611–20. doi: 10.1016/j.eururo.2018.05.002
  18. Gross-Goupil M., Kwon T.G., Eto M. et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29(12):2371–8. doi: 10.1093/annonc/mdy454
  19. Ravaud A., Motzer R.J., Pandha H.S. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375(23):2246–54. doi: 10.1056/NEJMoa1611406
  20. Choueiri T.K., Tomczak P., Park S.H. et al. Overall Survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 2024;390(15):1359–71. doi: 10.1056/NEJMoa2312695

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.